Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evogliptin Versus Linagliptin for the Effect on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency: a Multicenter, Randomised, Double-blind, Active-controlled, Non-inferiority Trial

NCT03667300 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03667300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03667300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evogliptin Versus Linagliptin for the Effect on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency: a Multicenter, Randomised, Double-blind, Active-controlled, Non-inferiority Trial
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
March 16, 2017
Completion date
May 14, 2019
Enrollment
209 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

albuminuria, renal insufficiency, type2 diabetes mellitus